source
- Regeneron signs up to $125 million deal with Parabilis to target difficult drug targetsRegeneron announced a deal with Parabilis Medicines valued up to $2.2 billion, with an upfront payment of $125 million. The agreement aims to give Regeneron access to Parabilis’s platform that dis…
- Supreme Court Declines to Hear Lawsuits Against Medicare Drug Price Negotiation ProgramThe U.S. Supreme Court on Monday refused to hear challenges to the Medicare drug price negotiation program, delivering a setback to the pharmaceutical industry's legal effort. The Court declined t…